- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02084758
Nitrate Supplementation in Chronic Obstructive Pulmonary Disease (COPD)
February 3, 2017 updated by: Maastricht University Medical Center
The Effects of Dietary Nitrate Supplementation on Metabolic Efficiency in Patients With COPD
Each subject will consume (in a randomized fashion) both the intervention beverage (nitrate solution) and the placebo, separated by a 1 wk washout period.
The investigators will test the hypothesis that 7 days of dietary nitrate supplementation will improve metabolic efficiency in patients with COPD compared to the placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands
- Maastricht University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- COPD
- Indication metabolic inefficiency
Exclusion Criteria:
- Sodium intake limitation
- Long-term oxygen therapy
- Severe renal impairment
- Use of medications that may interact with nitrate
- Contra-indications for performing (sub)maximal cycle ergometry
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Nitrate supplementation
Sodium nitrate solution
|
7 days of supplementation with sodium nitrate solution
7 days of supplementation with sodium chloride solution
|
|
Placebo Comparator: Placebo supplementation
Sodium chloride solution
|
7 days of supplementation with sodium nitrate solution
7 days of supplementation with sodium chloride solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in metabolic efficiency during exercise
Time Frame: Baseline, day 7, day 14 and day 21.
|
Metabolic efficiency (degree of efficiently used energy during exercise) will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks.
|
Baseline, day 7, day 14 and day 21.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in blood pressure during exercise
Time Frame: Baseline, day 7, day 14 and day 21.
|
Change in blood pressure will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks.
|
Baseline, day 7, day 14 and day 21.
|
|
Change in dyspnea during exercise
Time Frame: Baseline, day 7, day 14 and day 21.
|
Change in dyspnea will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks.
|
Baseline, day 7, day 14 and day 21.
|
|
Change in cycle endurance time during exercise.
Time Frame: Baseline, day 7, day 14 and day 21.
|
Change in cycle endurance time will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks.
|
Baseline, day 7, day 14 and day 21.
|
|
Change in oxygen uptake (VO2 mL/min) during exercise
Time Frame: Baseline, day 7, day 14 and day 21
|
Change in oxygen uptake will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks.
|
Baseline, day 7, day 14 and day 21
|
|
Change in Resting Energy Expenditure (REE)
Time Frame: Baseline, day 7, day 14 and day 21
|
Change in REE will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks.
|
Baseline, day 7, day 14 and day 21
|
|
Change in plasma concentrations of nitrate and nitrite, glucose, insulin, lactate and free fatty acids, IFABP and cardiac troponin
Time Frame: Baseline, day 7, day 14 and day 21
|
Change in these plasma concentrations will be assessed during the test days before and after the two supplementation periods (active and placebo) for a total timespan of 3 weeks.
|
Baseline, day 7, day 14 and day 21
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
VO2max and Wmax
Time Frame: Baseline
|
Baseline
|
|
|
height, body weight and body mass index (BMI)
Time Frame: Baseline
|
Baseline
|
|
|
Fat free mass and fat mass
Time Frame: Baseline
|
Fat free mass and fat mass determined by DEXA-scan
|
Baseline
|
|
Lung function
Time Frame: Baseline
|
Baseline
|
|
|
Physical activity
Time Frame: During the two supplementation periods
|
During the two supplementation periods
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Annemie Schols, Prof., Maastricht University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Actual)
October 1, 2016
Study Completion (Actual)
October 1, 2016
Study Registration Dates
First Submitted
February 17, 2014
First Submitted That Met QC Criteria
March 10, 2014
First Posted (Estimate)
March 12, 2014
Study Record Updates
Last Update Posted (Estimate)
February 6, 2017
Last Update Submitted That Met QC Criteria
February 3, 2017
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABR-47701
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Nitrate supplementation
-
Queen Mary University of LondonRecruitingHealthy Volunteers | Vascular Function | Nitric OxideUnited Kingdom
-
University of Texas Southwestern Medical CenterTexas Health ResourceCompletedMenopause | Early MenopauseUnited States
-
Capital Medical UniversityUnknownNasopharyngeal CarcinomaChina
-
University of VirginiaCompletedArterial Stiffness | Vascular DilationUnited States
-
Northumbria UniversityManchester Metropolitan UniversityCompleted
-
Queen's UniversityCompletedHeart Failure, Systolic
-
University of VirginiaRecruitingPeripheral Arterial Disease | Peripheral Vascular DiseasesUnited States
-
Wuerzburg University HospitalCompleted
-
Göteborg UniversityNot yet recruiting
-
Karolinska InstitutetKarolinska University HospitalCompletedHypertension | Cardiovascular DiseaseSweden